HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma
Journal of Clinical Investigation · 17.06.2024 · 134 (12)
DOI: 10.1172/jci164249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.06.2024. Verfasst von Zachary A Bacigalupa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Basic Helix-Loop-Helix Proteins, Kidney Neoplasms, Acetate-CoA Ligase. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is an aggressive cancer driven by VHL loss and aberrant HIF-2α signaling. Identifying means to regulate HIF-2α thus has potential therapeutic benefit. Acetyl-CoA synthetase 2 (ACSS2) converts acetate to acetyl-CoA and is associated with poor patient prognosis in ccRCC. Here we tested the effects of ACSS2 on HIF-2α and cancer cell metabolism and growth in ccRCC models and clinical samples. ACSS2 inhibition reduced HIF-2α levels and suppressed ccRCC cell line growth in vitro, in vivo, and in cultures of primary ccRCC patient tumors. This treatment reduced glycolytic signaling, cholesterol metabolism, and mitochondrial integrity, all of which are consistent with loss of HIF-2α. Mechanistically, ACSS2 inhibition decreased chromatin accessibility and HIF-2α expression and stability. While HIF-2α protein levels are widely regulated through pVHL-dependent proteolytic degradation, we identify a potential pVHL-independent pathway of degradation via the E3 ligase MUL1. We show that MUL1 can directly interact with HIF-2α and that overexpression of MUL1 decreased HIF-2α levels in a manner partially dependent on ACSS2. These findings identify multiple mechanisms to regulate HIF-2α stability and ACSS2 inhibition as a strategy to complement HIF-2α–targeted therapies and deplete pathogenically stabilized HIF-2α.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine.
- Department of Pathology, Microbiology, and Immunology, and.
- Vanderbilt Center for Immunobiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
- Cell Imaging Shared Resource, Vanderbilt University, Nashville, Tennessee, USA.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Bacigalupa, Z. A., Arner, E. N., Vlach, L. M., Wolf, M. M., Brown, W. A., Krystofiak, E. S., Ye, X., Hongo, R. A., Landis, M., Amason, E. K., Beckermann, K. E., Rathmell, W. K., & Rathmell, J. C. (2024). HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. Journal of Clinical Investigation, 134(12). https://doi.org/10.1172/jci164249
Vancouver
Bacigalupa ZA, Arner EN, Vlach LM, Wolf MM, Brown WA, Krystofiak ES, et al. HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma. Journal of Clinical Investigation. 2024;134(12). doi:10.1172/jci164249
BibTeX
@article{Bacigalupa2024,
author = {Bacigalupa, Zachary A and Arner, Emily N and Vlach, Logan M and Wolf, Melissa M and Brown, Whitney A and Krystofiak, Evan S and Ye, Xiang and Hongo, Rachel A and Landis, Madelyn and Amason, Edith K and Beckermann, Kathryn E and Rathmell, W Kimryn and Rathmell, Jeffrey C},
title = {HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {12},
doi = {10.1172/jci164249}
}
EUVIMED